Sequana Medical NV (SEQUA) | Stock Overview & Key Data
Sequana Medical NV | Small-cap | Healthcare
Sequana Medical NV | Small-cap | Healthcare
Sequana Medical NV Performance Comparison
Stock Range
Today's Range
Low: €1.17
High: €1.34
on August 8, 2025
52 Week Range
Low: €0.47
High: €4.39
on October 1, 2024
on December 27, 2024
All-Time High: €12.40 on January 4, 2021
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€87.3M
EPS
-1.22
P/E Ratio (TTM)
N/A
Forward P/E
-1.24
P/B Ratio
N/A
PEG Ratio
-1.24
Div. Yield
N/A
ROE
100.62%
Beta
0.013
Debt to Equity
-0.90
Financial Highlights
Profitability
Gross Margin
84.98%
Operating Margin
-17,731.38%
Profit Margin
74.94%
Returns and Earnings
Return on Assets (TTM)
-116.66%
Return on Equity (TTM)
100.62%
EBITDA
€-18.4M
Net Income (TTM)
€-44.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.00
Quarterly Revenue Growth (YoY)
-100.00%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sequana Medical NV SEQUA | 87.33M Small-cap | -10.87% | -8.21% | 11.82% | -32.04% | -49.80% | 26.80% | -79.22% | -79.90% |
| Ion Beam IBAB | 333.50M Mid-cap | -2.40% | 0.88% | 2.52% | -15.56% | -16.42% | -5.32% | -34.10% | 40.74% |
| Argenx SE ARGX | 36.23B Large-cap | -2.70% | 22.47% | 16.88% | -10.26% | -6.94% | 16.76% | 55.26% | 187.94% |
| UCB S.A UCB | 35.08B Large-cap | -0.19% | 8.47% | 21.66% | -3.50% | -3.58% | 17.07% | 152.26% | 80.18% |
| Fagron NV FAGR | 1.53B Large-cap | -2.83% | -6.15% | -3.51% | 5.75% | 22.91% | 7.85% | 48.74% | 8.08% |
| Nyxoah S.A NYXH | 246.76M Mid-cap | -1.07% | -4.58% | 13.93% | -38.48% | -24.88% | -16.75% | -37.40% | -66.87% |
Ownership & Short Interest
Insider Ownership
21.81%
Institutional Ownership
38.88%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
333K
Average 90-Day Volume
346K
Sequana Medical NV Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sequana Medical NV would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SEQUA's 52-week high and low?
- In the last 52 weeks, Sequana Medical NV reached a high of €4.39 (on December 27, 2024) and a low of €0.47 (on October 1, 2024).
- What is the market cap and P/E ratio for SEQUA?
- Curious about Sequana Medical NV's size and valuation? Its market capitalization stands at 87.33M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -1.24.
- Does SEQUA pay dividends? If so, what's the yield?
- As for dividends, Sequana Medical NV isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sequana Medical NV's main competitors or similar companies to consider before investing?
When looking at Sequana Medical NV, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Ion Beam
IBAB333.50M Healthcare Medical Devices -5.32% -34.10% Argenx SE
ARGX36.23B Healthcare Biotechnology 16.76% 55.26% UCB S.A
UCB35.08B Healthcare Biotechnology 17.07% 152.26% Fagron NV
FAGR1.53B Healthcare Drug Manufacturers - Specialty & Generic 7.85% 48.74% Nyxoah S.A
NYXH246.76M Healthcare Medical Instruments & Supplies -16.75% -37.40% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sequana Medical NV? (e.g., ROE, Debt/Equity)
- To get a sense of Sequana Medical NV's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 100.62%, the Debt to Equity ratio from the most recent quarter is -0.90, and its Gross Profit Margin stands at 84.98%.
- What is the recent revenue and earnings growth for SEQUA?
- Looking at Sequana Medical NV's growth, its revenue over the trailing twelve months (TTM) was €106K. Compared to the same quarter last year (YoY), quarterly revenue grew by -100.00%, and quarterly earnings saw a YoY growth of N/A.
- How much of SEQUA stock is held by insiders and institutions?
- Wondering who owns Sequana Medical NV stock? Company insiders (like executives and directors) hold about 21.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 38.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.